Valkyrie Clinical Trials, Inc.

Valkyrie Clinical Trials is a US-based company specializing in oncology clinical research, offering personalized support for trial participants to enhance their treatment journey through comprehensive consultations and assessments. Founded in 2021 and headquartered in Los Angeles, US, Valkyrie Clinical Trials focuses on providing clinical research services in oncology. The company has engaged in a single deal with its most recent transaction dated October 6, 2025, indicating active participation in the clinical research market. Valkyrie Clinical Trials (VCT) specializes in clinical research focused on oncology, providing trial participants with personalized support.

Its core offerings include no-cost eligibility consultations, where clinical research coordinators assess individuals for participation in trials addressing various cancer types. VCT facilitates the trial experience by coordinating necessary imaging, laboratory work, and follow-up appointments. With a multilingual staff catering to a diverse clientele, the company primarily serves cancer patients, particularly in California and surrounding areas. Valkyrie Clinical Trials generates revenue through its clinical research services involving direct interactions with potential trial participants.

Clients engage with VCT for eligibility assessments and opportunities to participate in oncology trials, with revenue streams including fees for trial management and patient care services, as well as partnerships with pharmaceutical companies for patient enrollment. In October 2025, Valkyrie Clinical Trials was acquired by Flourish Research, a portfolio company of Genstar Capital Partners, although financial terms were not disclosed. This acquisition is expected to support Flourish Research's growth initiatives. Future plans may focus on the development of new clinical research services and expanding into additional geographic markets to enhance patient engagement.